{"id":70287,"date":"2026-09-16T17:01:00","date_gmt":"2026-09-16T10:01:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=70287"},"modified":"2026-09-16T17:01:00","modified_gmt":"2026-09-16T10:01:00","slug":"nona-biosciences-successfully-develops-worlds-first-language-model-trained-on-fully-human-heavy-chain-only-antibodies","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=70287","title":{"rendered":"Nona Biosciences Successfully Develops World’s First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, Sept. 16, 2026<\/span> \/PRNewswire\/ — Nona Biosciences (“Nona”), a global biotechnology company advancing biologics discovery and development through innovative\u00a0technology platforms, today announced the development of HCAbLM, the world’s first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). HCAbLM was built on a large-scale repertoire comprising 31.8 million fully human HCAb sequences from 73 independently immunized HCAb transgenic mice. The study, “A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies,” was published in bioRxiv<\/a>.<\/p>\n

<\/div>\n

From Binder to Drug Candidate: A Leap in AI Antibody Development<\/b><\/p>\n

The main bottleneck in the current AI antibody field is no longer “whether an antibody that binds the target can be designed,” but rather “whether the designed antibody can be manufactured at scale, whether it will aggregate, and whether it is stable”\u2014that is, developability. HCAbLM was created precisely to address this issue. The model has learned the “sequence grammar” unique to fully human HCAbs\u2014a set of underlying rules that determine whether an antibody can fold, exist stably, and ultimately become a drug. Conventional general-purpose models cannot capture this set of rules because their training data contain almost no HCAb sequences. HCAbLM fully demonstrates that a dedicated model trained on unique antibody sequence data can better translate “<\/span>sequence space cognition“<\/span> into “<\/span>developability prediction.“<\/span><\/p>\n

A Dedicated HCAb Model Outperforms General-Purpose Protein and Antibody Models<\/b><\/p>\n

The representations learned by HCAbLM demonstrate transferability to experimentally measured antibody properties, including size exclusion chromatography (SEC) purity, hydrophobic interaction chromatography (HIC) behavior, and thermal stability, highlighting HCAbLM’s potential in the evaluation and optimization of fully human HCAbs, going beyond mere sequence analysis.<\/p>\n

In public benchmarks for cross-project developability prediction, HCAbLM, with only 366 million parameters, surpassed general-purpose protein large models including Meta’s ESM-6B with 6 billion parameters, as well as previously leading antibody language models IgLM and AbLang, on two core metrics: SEC purity and HIC behavior.<\/p>\n

The development of HCAbLM marks an important advancement in Nona’s application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody repertoires with AI-driven modeling, Nona is building a foundation for more efficient and data-driven antibody design and developability assessment.<\/p>\n

“The development of HCAbLM represents an important step in our efforts to apply AI to specialized antibody formats and unlock the value of large-scale antibody repertoires,” said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. “By learning the unique sequence characteristics of fully human HCAbs and demonstrating transferability to experimentally measured molecular properties, HCAbLM provides a new foundation for AI-enabled antibody discovery and development. We look forward to further integrating HCAbLM with Nona’s technology platforms, and leveraging these capabilities to accelerate antibody discovery and development while empowering our partners to unlock new opportunities for next-generation biotherapeutics.”<\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), is a global biotechnology company committed to advancing biotherapeutic innovation through cutting-edge technology platforms and integrated solutions. Nona supports programs with\u00a0its<\/span> I to\u00a0I\u00ae<\/sup>\u00a0framework, from early-stage ideas through preclinical research and advancement toward IND and early clinic, spanning target validation and antibody discovery to early development.<\/p>\n

Nona’s proprietary Harbour Mice\u00ae<\/sup>\u00a0technology platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice\u00ae<\/sup>\u00a0is the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.<\/p>\n

By integrating Harbour Mice\u00ae<\/sup>, single-B cell screening technology, NonaCarFx\u2122\u00a0(a direct CAR-function-based screening platform), Hu-mAtrIx\u2122\u00a0(an AI-driven drug discovery platform), Modalities-on-Demand\u00ae<\/sup>\u00a0(a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, Sept. 16, 2026<\/span> \/PRNewswire\/ — Nona Biosciences (“Nona”), a global biotechnology company advancing biologics discovery and development through innovative\u00a0technology platforms, today announced the development of HCAbLM, the world’s first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). HCAbLM was built on a large-scale repertoire comprising 31.8 million fully human HCAb sequences from 73 independently immunized HCAb transgenic mice. The study, “A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies,” was published in bioRxiv<\/a>.<\/p>\n

<\/div>\n

From Binder to Drug Candidate: A Leap in AI Antibody Development<\/b><\/p>\n

The main bottleneck in the current AI antibody field is no longer “whether an antibody that binds the target can be designed,” but rather “whether the designed antibody can be manufactured at scale, whether it will aggregate, and whether it is stable”\u2014that is, developability. HCAbLM was created precisely to address this issue. The model has learned the “sequence grammar” unique to fully human HCAbs\u2014a set of underlying rules that determine whether an antibody can fold, exist stably, and ultimately become a drug. Conventional general-purpose models cannot capture this set of rules because their training data contain almost no HCAb sequences. HCAbLM fully demonstrates that a dedicated model trained on unique antibody sequence data can better translate “<\/span>sequence space cognition“<\/span> into “<\/span>developability prediction.“<\/span><\/p>\n

A Dedicated HCAb Model Outperforms General-Purpose Protein and Antibody Models<\/b><\/p>\n

The representations learned by HCAbLM demonstrate transferability to experimentally measured antibody properties, including size exclusion chromatography (SEC) purity, hydrophobic interaction chromatography (HIC) behavior, and thermal stability, highlighting HCAbLM’s potential in the evaluation and optimization of fully human HCAbs, going beyond mere sequence analysis.<\/p>\n

In public benchmarks for cross-project developability prediction, HCAbLM, with only 366 million parameters, surpassed general-purpose protein large models including Meta’s ESM-6B with 6 billion parameters, as well as previously leading antibody language models IgLM and AbLang, on two core metrics: SEC purity and HIC behavior.<\/p>\n

The development of HCAbLM marks an important advancement in Nona’s application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody repertoires with AI-driven modeling, Nona is building a foundation for more efficient and data-driven antibody design and developability assessment.<\/p>\n

“The development of HCAbLM represents an important step in our efforts to apply AI to specialized antibody formats and unlock the value of large-scale antibody repertoires,” said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. “By learning the unique sequence characteristics of fully human HCAbs and demonstrating transferability to experimentally measured molecular properties, HCAbLM provides a new foundation for AI-enabled antibody discovery and development. We look forward to further integrating HCAbLM with Nona’s technology platforms, and leveraging these capabilities to accelerate antibody discovery and development while empowering our partners to unlock new opportunities for next-generation biotherapeutics.”<\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), is a global biotechnology company committed to advancing biotherapeutic innovation through cutting-edge technology platforms and integrated solutions. Nona supports programs with\u00a0its<\/span> I to\u00a0I\u00ae<\/sup>\u00a0framework, from early-stage ideas through preclinical research and advancement toward IND and early clinic, spanning target validation and antibody discovery to early development.<\/p>\n

Nona’s proprietary Harbour Mice\u00ae<\/sup>\u00a0technology platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice\u00ae<\/sup>\u00a0is the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.<\/p>\n

By integrating Harbour Mice\u00ae<\/sup>, single-B cell screening technology, NonaCarFx\u2122\u00a0(a direct CAR-function-based screening platform), Hu-mAtrIx\u2122\u00a0(an AI-driven drug discovery platform), Modalities-on-Demand\u00ae<\/sup>\u00a0(a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-70287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/70287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70287"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/70287\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}